← Oncology Approval Tracker

FDA DECISION ·

Loqtorzi

toripalimab-tpzi · Coherus BioSciences

FDA approvalNew therapyHead and neck cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Single-agent treatment for adults with recurrent unresectable or metastatic nasopharyngeal carcinoma that progressed during or after platinum-containing chemotherapy.

LAMPGEN ANALYSIS

Why it matters

A separate indication allowed monotherapy in the post-platinum setting.

What research teams should watch

Document the timing of progression relative to platinum and apply the single-agent evidence to the intended treatment line.

PRIMARY RECORDS

Sources